Emergent Biosolutions Inc

NYSE:EBS  
57.13
-0.34 (-0.59%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.05B
Current PE10.20
Forward PE 7.27
2yr Forward PE 11.18
See more stats
Estimates Current Quarter
Revenue$486.84 Million
Adjusted EPS$2.44
See more estimates
10-Day MA$58.54
50-Day MA$61.73
200-Day MA$77.78
See more pivots

Emergent Biosolutions Inc Stock, NYSE:EBS

400 Professional Drive, Suite 400, Gaithersburg, Maryland 20879
United States of America
Phone: +1.240.631.3200
Number of Employees: 2200

Description

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.